Streetbeat News

ANPCY

Angle

https://www.angleplc.com/

CEO

Andrew Newland

Industry

Surgical and Medical Instrument Manufacturing

Open

1.43

Mkt cap

51M

Volume

215

High

1.50

P/E Ratio

-1.74

52-wk high

4.00

Low

1.43

Div yield

N/A

52-wk low

0.74

ANGLE PLC presented new data at a cancer research conference, highlighting advances in cancer diagnostics with its Parsortix-based assays for lung and breast cancer.

Portfolio Pulse from

November 15, 2024 | 8:00 am

ANGLE PLC's Parsortix system shows potential in improving treatment tracking and identifying drug-resistant cases in non-small cell lung cancer (NSCLC) by analyzing circulating tumor cells and DNA. The study involved patients treated with AstraZeneca's osimertinib.

Portfolio Pulse from

November 11, 2024 | 7:45 am

ANGLE has signed a supplier agreement with AstraZeneca to develop a Parsortix-based androgen receptor (AR) detection assay for prostate cancer studies, valued at £550,000. The development will occur in ANGLE's UK labs, aiming for completion in Q1 2025. Success could highlight Parsortix's role in evaluating prostate cancer treatments and promise ongoing business for ANGLE in supporting clinical studies.

Portfolio Pulse from Benzinga Newsdesk

May 03, 2024 | 7:06 am

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.